Filgrastim Recruiting Phase 1 Trials for NY-ESO-1 Positive / Unresectable Malignant Neoplasm / Locally Advanced Malignant Neoplasm / HLA-A*0201 Positive Cells Present Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03240861Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer